Literature DB >> 15990089

Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.

Connie Brouwer1, Trude M Vogels-Mentink, Jenneke J Keizer-Garritsen, Frans J M Trijbels, Jos P M Bökkerink, Peter M Hoogerbrugge, Elisabeth R van Wering, Anjo J P Veerman, Ronney A De Abreu.   

Abstract

Thiopurines are used for treatment of several diseases. Cytotoxicity is caused by the derived compounds 6-thioguanine nucleotides (TGNs) and methyl-6-thioinosine monophosphate (methylthio-IMP). The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5'-nucleotidase. It has been shown that the various 5'-nucleotidases are key enzymes for (6-thio)-purine metabolism. We aimed to investigate whether the overall 5'-nucleotidase (5'NT) activity is correlated with the efficacy and toxicity of 6-thiopurine nucleotides. Substrate affinity of 5'NT for IMP, GMP, AMP, thio-IMP, thio-GMP and methylthio-IMP was studied in human lymphocytes. For each of the substrates, the pH for optimal overall enzyme activity has been determined at a pH range between 6 and 10. At the optimal pH, assays were performed to establish Km and Vmax values. Optimal pH values for the various substrates were between 7 and 8.5. Km values ranged from 33 to 109 microM, Vmax ranged from 3.99 to 19.5 nmol/10(6) peripheral mononuclear cells (pMNC) h, and Vmax/Km ratios ranged from 105 to 250. The results did not show a distinct preference of 5'NT activity for any of the tested thiopurine nucleotides. The enzyme kinetic studies furthermore revealed substrate inhibition by thio-IMP and thio-GMP as a substrate. Inhibition by thio-GMP also seems to occur in patients treated with 6-mercaptopurine (6 MP); subsequently, this may lead to toxicity in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990089     DOI: 10.1016/j.cccn.2005.05.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

Review 1.  Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.

Authors:  Chelsea L Dieck; Adolfo Ferrando
Journal:  Blood       Date:  2019-03-25       Impact factor: 22.113

2.  Resistance revealed in acute lymphoblastic leukemia.

Authors:  Jon C Aster; Daniel J DeAngelo
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

Review 3.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia.

Authors:  Laura Belver; Adolfo Ferrando
Journal:  Nat Rev Cancer       Date:  2016-07-25       Impact factor: 60.716

4.  Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.

Authors:  Chelsea L Dieck; Gannie Tzoneva; Farhad Forouhar; Zachary Carpenter; Alberto Ambesi-Impiombato; Marta Sánchez-Martín; Renate Kirschner-Schwabe; Scott Lew; Jayaraman Seetharaman; Liang Tong; Adolfo A Ferrando
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

Review 5.  The genetics and molecular biology of T-ALL.

Authors:  Tiziana Girardi; Carmen Vicente; Jan Cools; Kim De Keersmaecker
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

Review 6.  Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.

Authors:  Hong-Li Guo; Yue-Tao Zhao; Wei-Jun Wang; Na Dong; Ya-Hui Hu; Yuan-Yuan Zhang; Feng Chen; Li Zhou; Tao Li
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

7.  Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Authors:  Gannie Tzoneva; Arianne Perez-Garcia; Zachary Carpenter; Hossein Khiabanian; Valeria Tosello; Maddalena Allegretta; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Jana Hof; Renate Kirschner-Schwabe; Teresa Palomero; Raul Rabadan; Adolfo Ferrando
Journal:  Nat Med       Date:  2013-02-03       Impact factor: 53.440

8.  Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.

Authors:  Gannie Tzoneva; Chelsea L Dieck; Koichi Oshima; Alberto Ambesi-Impiombato; Marta Sánchez-Martín; Chioma J Madubata; Hossein Khiabanian; Jiangyan Yu; Esme Waanders; Ilaria Iacobucci; Maria Luisa Sulis; Motohiro Kato; Katsuyoshi Koh; Maddalena Paganin; Giuseppe Basso; Julie M Gastier-Foster; Mignon L Loh; Renate Kirschner-Schwabe; Charles G Mullighan; Raul Rabadan; Adolfo A Ferrando
Journal:  Nature       Date:  2018-01-17       Impact factor: 49.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.